This is not only true for ß-arrestin activation by the FDA-approved “ß-blocker,” carvedilol, in CHF, but also ß-arrestin activation in other GPCRs such as the angiotensin AT1 receptor (Kim et al., 2012; Monasky et al., 2013). This evidence concerns the gene SAG and congestive heart failure.